Gland Pharma Limited (BOM:543245)

Market Cap	236.13B
Revenue (ttm)	57.29B
Net Income (ttm)	7.04B
Shares Out	n/a
EPS (ttm)	42.76
PE Ratio	33.52
Forward PE	24.85
Dividend	20.00 (1.40%)
Ex-Dividend Date	n/a

Volume	6,997
Average Volume	17,326
Open	1,426.35
Previous Close	1,426.30
Day's Range	1,419.95 - 1,452.25
52-Week Range	1,200.00 - 2,220.95
Beta	n/a
RSI	44.68
Earnings Date	May 20, 2025

About Gland Pharma

Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. The company engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company offers its products for various therapeutic categories, such as anti-malarial, anti-infectives, anti-neoplastic, blood ...

• Industry: Pharmaceutical Preparations
• Founded: 1978
• Employees: 4,217
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 543245

Financial Performance

In 2023, Gland Pharma's revenue was 56.65 billion, an increase of 56.29% compared to the previous year's 36.25 billion. Earnings were 7.72 billion, a decrease of -1.10%.